Table 4. Minimum inhibitory concentrations of besifloxacin and comparator antibacterial agents for baseline isolates from poly- and monobacterial conjunctivitis infections.
| MIC (μg/mL | Besi | Moxi | Gati | Levo | Cipro | Oflox | Azi | |
|---|---|---|---|---|---|---|---|---|
| Polybacterial Infections | ||||||||
| All isolates (n = 387) | Range | 0.015–8 | 0.008–>8 | 0.008–>8 | 0.008–>8 | 0.008–>8 | 0.008–>8 | 0.008–>8 |
| MIC90 | 0.5 | 1 | 1 | 2 | 4 | 2 | >8 | |
| Gram-positive isolates (n = 286) | Range | 0.015–4 | 0.008–>8 | 0.008–>8 | 0.008–>8 | 0.015–>8 | 0.008–>8 | 0.008–>8 |
| MIC90 | 0.5 | 2 | 2 | 4 | 8 | 8 | >8 | |
| Gram-negative isolates (n = 101) | Range | 0.015–8 | 0.015–8 | 0.008–8 | 0.008–8 | 0.015->8 | 0.03->8 | 0.015->8 |
| MIC90 | 2 | 1 | 1 | 1 | 1 | 2 | >8 | |
| S. aureus (n = 73) | Range | 0.015–4 | 0.03–>8 | 0.03–>8 | 0.03–>8 | 0.06–>8 | 0.125–>8 | 0.06–>8 |
| MIC90 | 0.5 | 2 | 2 | 4 | >8 | 8 | >8 | |
| H. influenzae (n = 51) | Range | 0.015–0.5 | 0.015–1 | 0.008–0.5 | 0.008–1 | 0.008–1 | 0.03–2 | 0.015–4 |
| MIC90 | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 | 0.06 | 2 | |
| S. epidermidis (n = 41) | Range | 0.03–4 | 0.06–>8 | 0.125–>8 | 0.25–>8 | 0.125–>8 | 0.5–>8 | 0.5–>8 |
| MIC90 | 0.5 | 4 | 4 | 8 | >8 | >8 | >8 | |
| S. mitis/S. mitis group (n = 34) | Range | 0.03–1 | 0.06–2 | 0.25–2 | 0.5->8 | 0.5->8 | 1->8 | 0.03->8 |
| MIC90 | 0.25 | 0.25 | 1 | 2 | 4 | 4 | 8 | |
| S. pneumoniae (n = 29) | Range | 0.06–0.25 | 0.06–1 | 0.125–0.5 | 0.5–2 | 0.25–2 | 1–4 | 0.125->8 |
| MIC90 | 0.125 | 0.25 | 0.5 | 1 | 2 | 2 | >8 | |
| S. oralis (n = 14) | Range | 0.125–0.25 | 0.015–0.5 | 0.03–1 | 0.125–2 | 0.03–4 | 0.125–4 | 0.0.06–>8 |
| MIC90 | 0.25 | 0.25 | 1 | 2 | 4 | 4 | >8 | |
| CDC Coryneform Group G (n = 10) | Range | 0.015–2 | 0.06->8 | 0.03–8 | 0.06->8 | 0.03–8 | 0.125->8 | 0.06->8 |
| MIC90 | 2 | >8 | 8 | >8 | 8 | >8 | >8 | |
| Monobacterial Infections | ||||||||
| All isolates (n = 864) | Range | 0.008–8.0 | ≤0.004->8 | ≤0.004->8 | ≤0.004->8 | ≤0.004->8 | 0.015->8 | 0.015->8 |
| MIC90 | 0.125 | 0.25 | 0.5 | 1 | 1 | 2 | >8 | |
| Gram-positive isolates (n = 537) | Range | 0.008–8.0 | 0.015->8 | 0.015->8 | 0.03->8 | 0.015->8 | 0.06->8 | 0.015->8 |
| MIC90 | 0.125 | 0.25 | 0.5 | 1 | 2 | 2 | >8 | |
| Gram-negative isolates (n-327) | Range | 0.008–8.0 | ≤0.004–4 | ≤0.004–4 | ≤0.004–4 | ≤0.004->8 | 0.015–8 | 0.015->8 |
| MIC90 | 0.125 | 0.125 | 0.125 | 0.125 | 0.06 | 0.25 | 4 | |
| S. aureus (n = 110) | Range | 0.008–8.0 | 0.03>8 | 0.03->8 | 0.06->8 | 0.06->8 | 0.125->8 | 1->8 |
| MIC90 | 1 | 2 | 4 | 8 | >8 | >8 | >8 | |
| H. influenzae (n = 288) | Range | 0.008–0.5 | 0.008–1 | ≤0.004–0.5 | ≤0.004–1 | ≤0.004–1 | 0.015–2 | 0.015->8 |
| MIC90 | 0.06 | 0.06 | 0.03 | 0.03 | 0.015 | 0.06 | 4 | |
| S. epidermidis (n = 54) | Range | 0.03–2.0 | 0.06->8 | 0.06->8 | 0.125->8 | 0.125->8 | 0.25->8 | 0.5->8 |
| MIC90 | 0.5 | 4 | 2 | 8 | >8 | >8 | >8 | |
| S. mitis/S. mitis group (n = 21) | Range | 0.03–0.25 | 0.03–0.5 | 0.06–1 | 0.125–2 | 0.06–4 | 0.25–4 | 0.03–8 |
| MIC90 | 0.25 | 0.25 | 0.5 | 2 | 2 | 2 | 8 | |
| S. pneumoniae (n = 272) | Range | 0.03–0.25 | 0.06–0.5 | 0.125–1 | 0.125–2 | 0.125->8 | 0.5–2 | 0.06->8 |
| MIC90 | 0.125 | 0.125 | 0.5 | 1 | 1 | 2 | >8 | |
| S. oralis (n = 3) | Range | 0.06–0.125 | 0.125–0.25 | 0.25–0.5 | 0.5–1 | 1–2 | 1–2 | 0.06–0.125 |
| MIC90 | — | — | — | — | — | — | — | |
| CDC Coryneform Group G (n = 13) | Range | 0.008–0.06 | 0.03–0.125 | 0.03–0.5 | 0.06–1 | 0.03–0.5 | 0.125–2 | 0.06->8 |
| MIC90 | 0.06 | 0.25 | 0.5 | 0.5 | 0.25 | 1 | >8 | |
MIC90: Minimum inhibitory concentration that inhibits growth of 90% of isolates
MIC data is only shown for those baseline species with ≥10 isolates in either subgroup
Azi, azithromycin; Besi, besifloxacin; Cipro, ciprofloxacin; Gati, gatifloxacin, Levo, levofloxacin; Moxi, moxifloxacin; Oflox, Ofloxacin